The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes among patients with advanced/metastatic renal cell carcinoma (mRCC) treated with cabozantinib or other tyrosine kinase inhibitors (TKIs) after checkpoint inhibitor (CPI) therapy.
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Gury K. Doshi
No Relationships to Disclose
 
Pascale Dutailly
Employment - Ipsen
 
Aude Houchard
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
Travel, Accommodations, Expenses - Ipsen
 
Mickael Lothgren
Employment - Amgen; Ipsen
Stock and Other Ownership Interests - Amgen
 
Alisha Monnette
Employment - Ontada/McKesson
Stock and Other Ownership Interests - McKesson
Research Funding - Bristol-Myers Squibb/Celgene (Inst); Clovis Oncology (Inst); G1 Therapeutics (Inst); Ipsen (Inst)
 
Yunfei Wang
Employment - Ontada/McKesson
Stock and Other Ownership Interests - McKesson
 
Valérie Perrot
Employment - Ipsen
Stock and Other Ownership Interests - Ipsen
Travel, Accommodations, Expenses - Ipsen
 
Aly-Khan A. Lalani
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Merck; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Pfizer; Roche/Genentech
Research Funding - BioCanRx (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Ipsen (Inst); Novartis (Inst); Roche (Inst)